By FieldPulse Editorial · March 24, 2026
Tags: FDA, Compliance, Oncology
The FDA has issued a warning letter to ImmunityBio and its founder Patrick Soon-Shiong over TV ads and podcast appearances that the agency said made false and misleading claims about Anktiva, a bladder cancer drug.
The FDA issued a warning letter to ImmunityBio and its founder and executive chairman Patrick Soon-Shiong on Monday, citing what the agency described as false and misleading promotional claims about Anktiva — the company's bladder cancer drug known generically as nogapendekin alfa inbakicept-pmln. According to the agency, the violations appeared in television advertisements and in podcast appearances made by Soon-Shiong himself. The FDA found that the promotional materials overstated the drug's efficacy and minimized its associated risks — two of the most serious categories of promotional viol